Alternatives to Epicrispr Biotechnologies
Epicrispr Biotechnologies is a Biotechnology tool: epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD). Here are the 60 closest alternatives, compared on pricing, features and what real users say.
Epicrispr Biotechnologies profileMore Biotechnology alternatives
The 20 closest Biotechnology companies to Epicrispr Biotechnologies
- Website
Moderna77BiotechnologyCambridge, United States$4.5BModerna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
- Website
Infinimmune60BiotechnologyAlameda, United States$75.0MDeveloping human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.
- Website
CellCentric60BiotechnologyCambridge, United Kingdom$375.0MA clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
- Website
LifeMine Therapeutics Inc.60BiotechnologyWatertown, United States$543.0MClinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.
- Website
Mironid59BiotechnologyGlasgow, United Kingdom$46.0MBiopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).
- Website
Freenome59BiotechnologySouth San Francisco, USA$570.0MFreenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.
- Website
Spark Therapeutics58BiotechnologyPhiladelphia, United States$82.8MA biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.
- Website
Rocket Pharmaceuticals57BiotechnologyCranbury, USA$382.9MA biotechnology company developing genetic therapies for rare disorders.
- Website
Verve Therapeutics56BiotechnologyCambridge, USA$300.0MDeveloping gene editing therapies to lower cholesterol.
- Website
Anagram Therapeutics55BiotechnologyNatick, USA$285.0MClinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.
- Website
Transcripta Bio54BiotechnologyPalo Alto, United States$24.0MAI-powered drug discovery company focused on neurological and neuromuscular diseases, leveraging transcriptomics to accelerate therapeutic development.
- Website
Latus Bio54BiotechnologyBoston, USA$151.0MEngineering scalable gene therapies for broader patient populations.
- Website SPSpliceBio54BiotechnologyCambridge, United States$100.0M
Biotechnology company developing next-generation gene therapies using a proprietary protein splicing platform.
- Website
Ray Therapeutics53BiotechnologyBerkeley, USA$243.0MPioneering vision restoration therapies for severe retinal degenerations.
- Website
SonoThera53BiotechnologySan Francisco, USA$125.0MDeveloping ultrasound-mediated nonviral genetic medicines.
- Website KHKhartis Therapeutics, Inc.53BiotechnologySan Diego, United States$50.0M
Developing oral small molecule medicines for immunological and chronic diseases.
- Website
Rejuvenate Bio52BiotechnologyCambridge, USA$6.0MDeveloping novel therapies to reverse aging and extend lifespan.
- Website
Immix Biopharma, Inc.51BiotechnologyLos Angeles, United States$5.0MA clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.
- Website
Travere Therapeutics51BiotechnologySan Diego, USA$63.0MA biopharmaceutical company focused on developing and commercializing therapies for rare diseases.
- Website LILife Biosciences49BiotechnologyBoston, USA$100.0M
Developing epigenetic reprogramming drugs for age restoration.
Showing the 20 closest matches. See the rest on the Epicrispr Biotechnologies profile.
Compare Epicrispr Biotechnologies head to head
Side by side on what each one does, what it costs, and what real users report.